Skip to content

Trial Summary

Positron Emission Tomography Imaging of Participants with Known or Suspected Gastroenteropancreatic Neuroendocrine Tumours Using 64Cu-SARTATE: A Multi-Centre, Single Arm, Non-Randomised, Blinded-Review, Phase II study

Acronym:

CLS07

ACTRN/NCT /ethics:

NCT04438304

Scientific title:

A Diagnostic Imaging Study of 64Cu-SARTATE Using PET on Patients With Known or Suspected Neuroendocrine Tumors

Sponsor / Cooperative group:

Clarity Pharmaceuticals Ltd

Trial & Patient Characteristics

Cancer TypeNeuroendocrine
Trial TypeEarly detection, diagnosis, prognosis
PhasePhase II
Age Range18 years and older
SexBoth
Tumour Stream -
Cancer StageAll stages
Anticipated Start Date2021-02-01
Anticipated End Date2022-01-08

Participating Hospitals

HospitalRoyal Adelaide Hospital
Clinical Trial CoordinatorAnne Milton
Emailanne.milton@sa.gov.au
Phone08 7074 2342
Principal InvestigatorDr Nimit Singhal
Recruitment StatusRecruiting